London, UK – [Date of Publication] – The European pharmaceutical market, a coveted destination for innovative medicines, presents a formidable challenge for emerging biotechs aiming for successful product launches. With 2025 seeing an impressive 193 innovative drugs approved in Europe, including 133 new molecular entities (NMEs), a significant portion of these breakthroughs originate from outside the continent. Over half (56%) of NME sponsors were non-European, and a substantial 27% were private companies. While established pharmaceutical giants often possess the resources to navigate this complex landscape, a considerable number of these sponsors, just over a quarter, are small to medium-sized enterprises (SMEs) that may lack the deep understanding and operational infrastructure required for a seamless European rollout.
Experts from Cencora, a leading pharmaceutical solutions provider, highlight that for these emerging players, securing regulatory approval is merely the first hurdle in a marathon of logistical, commercial, and regulatory complexities. Unlike the more unified healthcare market in the United States, Europe is a tapestry of 44 sovereign states, each with its distinct healthcare system, reimbursement frameworks, and third-party logistics (3PL) expectations. This intricate web is further complicated by a mosaic of languages and currencies, demanding a highly localized and adaptable approach that first-time launchers often underestimate.
The Multifaceted Challenges of a European Launch
The path to bringing a new therapy to European patients is fraught with potential pitfalls, extending far beyond the initial marketing authorization. One of the most immediate and tangible challenges lies in the supply chain. Local language requirements for product packaging and patient leaflets necessitate meticulous adaptation for each target market, adding significant time and cost. Furthermore, the EU’s stringent new serialization rules, mandating unique anti-counterfeiting identifiers on every individual pack, introduce another layer of operational complexity.
However, the challenges are not confined to physical distribution. Pricing, reimbursement, and market access systems are deeply fragmented across European nations. This disunity transforms Europe-wide access from a straightforward process into a potentially resource-intensive endeavor for marketing authorization (MA) holders. The stark reality of this fragmentation is evident in launch timelines. Data from the European Federation of Pharmaceutical Industries and Industries (EFPIA) reveals a staggering average of 578 days between market authorization and actual patient access across Europe. This average masks significant national variations, with Germany boasting a comparatively swift 128-day average, while Portugal lags behind at an arduous 840 days.
In response to this intricate landscape, companies often adopt a phased launch strategy. The typical approach prioritizes the "EU big 4" countries (Germany, France, Italy, and Spain) and the UK, drawn by their large patient populations and generally higher drug prices. This selective entry strategy allows companies to maximize revenue in carefully chosen markets while simultaneously mitigating the risks associated with international reference pricing and potential price adjustments that could impact U.S. pricing for American manufacturers.
Lessons from the Frontlines: What Can Go Wrong?
Cencora, through its acquisition of Alloga in 2021, has positioned itself as a major pharmaceutical 3PL partner across Europe, operating a central hub in the Netherlands for importing and distributing products. This extensive experience has provided invaluable insights into the common missteps that even established companies can make.
Gert Jan Van Der Hulst, VP of Integrated Solutions and Commercialisation at Cencora, shared a cautionary tale: "In one situation with an established partner, they were gearing up to launch but forgot a minor detail – the European Medicines Agency had to approve their U.S. manufacturing facilities. They thought it was done, it wasn’t, and it pushed out their launch by several months." This anecdote underscores a critical point: the need for early and comprehensive visibility into all regulatory requirements, not just those directly related to product approval.
The repercussions of such oversights are often severe, primarily manifesting as significant launch delays. "Early visibility into what distribution licenses you need as a company and when you need them is critical," Van Der Hulst emphasizes. "The same is applicable for a company’s choice for a European legal entity. Often Switzerland is considered, however, the country is not part of the European Union. You have an approved product, think you are ready to go, however, you cannot distribute your product across Europe. A legal entity in an EU member state is required for that."
David de Wit, Director of Regional Specialty Solutions at Cencora Alloga, echoes this sentiment, identifying postponed launches as one of the most significant pitfalls. He recounted another scenario where a company failed to secure its Wholesale Distribution Authorization (WDA) in a timely manner. The WDA is a non-negotiable license required to supply pharmaceuticals within Europe. "Emerging biotechs usually make promises to internal and/or external stakeholders that they are going to launch by a certain date, but we quite often see significant delays in the actual go-live date," de Wit stated. These delays not only impact revenue projections but can also erode trust with investors and healthcare providers.
The Strategic Imperative of Outsourcing and Partnerships
Given the inherent complexities, the question arises: is it possible to adhere to a European launch plan? The consensus among experts is a resounding yes, but it requires an exceptionally early start, meticulous planning, and robust administrative support. De Wit stresses the essential nature of local resources in critical areas such as market access, supply chain management, regulatory affairs, and pharmacovigilance. "In most cases, non-Europe-based clients don’t have boots on the ground in Europe, and you need them," he asserts. "Usually, that means they can benefit from outsourcing strategic activities to a company with extensive experience, like Cencora."
Outsourcing commercial services offers a compelling pathway for emerging biotechs to mitigate supply chain risks and accelerate their time-to-market. By leveraging the established infrastructure and expertise of a seasoned partner, these companies can bypass the considerable challenges and risks associated with building out a European footprint prematurely, before local country approvals are even secured. Van Der Hulst highlights Cencora’s strategic investment in its European presence and capabilities, emphasizing that their ownership of key elements required for commercial success reduces reliance on external partners who may have conflicting interests. This integrated approach allows biotechs to tap into a vast network of resources, local expertise, and robust infrastructure across Europe.
Embracing Lean 3PL Models for Streamlined Operations
Cencora’s suite of complementary services is specifically designed to address the hurdles encountered by emerging companies. These offerings aim to streamline the go-to-market process and alleviate the administrative burden. For instance, in France and Italy, Cencora actively participates in hospital tenders on behalf of MA holders, managing the preparation of compliant bids and ensuring on-time delivery once contracts are secured.
A particularly innovative service offered by Cencora addresses the critical risk of late-stage commercialization. De Wit explains the "Title Model," where Cencora can utilize its own Wholesale Distribution License (WDA) if a client has not yet obtained theirs. In this model, Cencora takes title of the product, a crucial solution for MA holders requiring a rapid pathway to market, especially when facing tight launch deadlines or unforeseen regulatory delays.
For companies that have not yet established business operations in Europe or wish to avoid the associated costs and risks, Cencora provides comprehensive order fulfillment solutions. This end-to-end service encompasses order reception, delivery scheduling, product dispatch, and invoice issuance. "We also take care of cash collection and the whole reminders process, and we then reconcile with the emerging biotech client every 10 days, for example," de Wit elaborates. "For the client, it’s a lean model where we act as the customer service agent to their end customers. We take orders locally from the end customers in the countries, but the order fulfillment is done centrally in our European hub, which gives them more efficiency in their supply chain." This lean approach allows emerging biotechs to focus on their core competencies – research and development – while entrusting the complex operational aspects of the European market to a trusted partner.
A Strategic Partnership: Unlocking European Potential
Bringing novel therapies to European patients is an undertaking of immense complexity, encompassing everything from securing regulatory licenses and orchestrating intricate launch strategies to navigating hospital tenders, ensuring timely deliveries, and meeting diverse order fulfillment demands across multiple countries. For emerging biotechs, particularly those based outside the region, these challenges can appear insurmountable when faced alone.
Van Der Hulst candidly observes, "In about nine out of ten cases, we’re engaging with companies who do not fully understand the European landscape and its requirements, either because they’ve been badly advised by external consultants or they simply did not have the time to do the proper desk research internally." This highlights a prevalent gap in knowledge and preparedness, often stemming from a lack of direct experience with the nuances of European healthcare systems.
Companies grappling with delayed launches and the complexities of market entry are in dire need of strategic services that can accelerate their speed-to-market, diminish administrative burdens, and significantly minimize the risks associated with establishing new operational teams and logistics infrastructure in unfamiliar territories. By partnering with Cencora, these emerging biotechs gain access to an expansive and robust European network, streamlined support services, and invaluable expertise. This strategic alliance not only unlocks new possibilities within the European market but also provides a solid foundation for future global expansion. The journey through Europe’s healthcare labyrinth is arduous, but with the right guidance and strategic partnerships, emerging biotechs can transform potential pitfalls into pathways for success.
About the Author
